Related Experiment Video

Updated: Sep 3, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Association between ApoA1 Gene, Plasma Lipid Profile, hsCRP Level, and Risk of Arterial Stiffness in Thai Elderly

Pruttaya Supajaree1, Suwannee Chanprasertyothin2, Prapimporn Chattranukulchai Shantavasinkul3

  • 1Master of Science Program in Nutrition, Faculty of Medicine Ramathibodi Hospital and Institute of Nutrition, Mahidol University, Bangkok, Thailand.

Advances in Preventive Medicine
|July 25, 2022
PubMed

Insights

Apolipoprotein A1 (ApoA1) rs670 gene variations are linked to arterial stiffness in older adults. The AA genotype was associated with lower arterial stiffness, suggesting a role for ApoA1 in vascular health.

Area of Science:

  • Cardiovascular Genetics
  • Biochemistry
  • Gerontology

Background:

  • Apolipoprotein A1 (ApoA1) gene polymorphism influences high-density lipoprotein cholesterol (HDL-C) levels.
  • Dyslipidemia and inflammation, potentially influenced by ApoA1 variations, are risk factors for vascular stiffness.
  • Arterial stiffness is a significant predictor of cardiovascular events in older populations.

Purpose of the Study:

  • To investigate the association between ApoA1 rs670 genetic variations and arterial stiffness in individuals aged 60 and above.
  • To explore the relationship between ApoA1 rs670 genotypes, biochemical parameters, and arterial stiffness.
  • To identify risk factors contributing to arterial stiffness in older adults.

Main Methods:

  • A population-based cross-sectional study involving 355 participants aged 60 years and older.
  • Data collection included questionnaires, clinical examinations, biochemical analyses, and ApoA1 rs670 genotyping using real-time PCR.
  • Arterial stiffness was assessed using the cardio-ankle vascular index (CAVI).

Main Results:

  • Age, BMI, waist circumference, SBP, LDL-C, and hs-CRP were associated with high CAVI (≥9).
  • The ApoA1 rs670 AA genotype group exhibited a lower mean CAVI (8.19 ± 2.78) compared to the GG genotype group (8.94 ± 1.00, p < 0.05).
  • Lower HDL-C (OR=0.47) and higher hs-CRP (OR=0.30) levels were independently associated with increased arterial stiffness.

Conclusions:

  • ApoA1 rs670 genetic variations, alongside factors like hypertension and inflammation, are implicated in arterial stiffness.
  • The findings suggest a potential protective role of the ApoA1 rs670 AA genotype against arterial stiffness in older adults.
  • Further research is warranted to elucidate the precise mechanisms linking ApoA1, HDL metabolism, and vascular health.
Abstract

More Related Videos

Measuring the Carotid to Femoral Pulse Wave Velocity Cf-PWV to Evaluate Arterial Stiffness05:51

Measuring the Carotid to Femoral Pulse Wave Velocity Cf-PWV to Evaluate Arterial Stiffness

Published on: May 3, 2018

17.7K
A Novel Stretching Platform for Applications in Cell and Tissue Mechanobiology16:46

A Novel Stretching Platform for Applications in Cell and Tissue Mechanobiology

Published on: June 3, 2014

11.8K

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
71
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
29
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
35
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
51
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31